Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent
19 Octubre 2017 - 12:00PM
Business Wire
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced
that the Patent Trials and Appeal Board (PTAB) of the U.S. Patent
and Trademark Office has denied Incyte’s petition to institute
inter partes review (IPR) of U.S. Patent No. 9,249,149 (the ‘149
patent). The denial of Incyte’s IPR petition upholds the validity
of the ‘149 patent that includes claims covering CTP-543, the
Company’s investigational compound for the treatment of alopecia
areata.
“We are very pleased that the PTAB did not institute the IPR,
and that our composition-of-matter patent relating to CTP-543
remains valid and enforceable,” stated Roger Tung, President and
Chief Executive Officer of Concert Pharmaceuticals. “This is the
second case in which the PTAB has elected not to institute an IPR
challenge to a deuterated compound based on a pre-existing drug and
further supports Concert’s technology approach.”
In April 2017, Incyte filed a petition challenging the validity
of the ‘149 patent. Documents relating to the IPR can be accessed
online at:
http://www.concertpharma.com/technology-overview/intellectual-property/
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical
company focused on applying its DCE Platform® (deuterated chemical
entity platform) to create novel medicines designed to address
unmet patient needs. The Company’s approach starts with approved
drugs in which deuterium substitution has the potential to enhance
clinical safety, tolerability or efficacy. Concert has a broad
pipeline of innovative medicines targeting autoimmune and
inflammatory diseases and central nervous systems (CNS) disorders.
For more information please visit www.concertpharma.com.
Cautionary Note on Forward Looking Statements
Any statements in this press release about our future
expectations, plans and prospects, including statements about the
strength of Concert’s intellectual property, and other statements
containing the words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “would,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including factors discussed in the “Risk Factors” section
of our most recent Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission and in other filings that we
make with the Securities and Exchange Commission. In addition, any
forward-looking statements included in this press release represent
our views only as of the date of this release and should not be
relied upon as representing our views as of any subsequent date. We
specifically disclaim any obligation to update any forward-looking
statements included in this press release.
Concert Pharmaceuticals Inc., the CoNCERT
Pharmaceuticals Inc. logo and DCE Platform are registered
trademarks of Concert Pharmaceuticals, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171019006221/en/
InvestorsConcert Pharmaceuticals, Inc.Justine Koenigsberg,
781-674-5284ir@concertpharma.comorMediaThe Yates NetworkKathryn
Morris, 845-635-9828kathryn@theyatesnetwork.com
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024